Search
for
Sort by
Research 361–390 of 1000+
- The Role of Sex and Gender in Dermatology - From Pathogenesis to Clinical Implications
- Poster Presentations
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients
- Bendamustine in Indolent Non-Hodgkin's Lymphoma: A Practice Guide for Patient Management
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Utilities of Botulinum Toxins in Dermatology and Cosmetology
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Skin manifestations associated with COVID-19
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Application of Baricitinib in Dermatology
- Applications of Marine Organism-Derived Polydeoxyribonucleotide: Its Potential in Biomedical Engineering
- Skin, a mirror reflecting diabetes mellitus: A longitudinal study in a tertiary care hospital in Gujarat
- Cold Plasma An emerging technology for clinical use in wound healing
- Ruxolitinib found to cause eyelash growth: a case report
- Photobiomodulation therapy
- Alopecia areata following COVID-19 vaccine: a systematic review
- Autophagy: Guardian of Skin Barrier
- Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
- Case Report: Rowell Syndrome–Like Flare of Cutaneous Lupus Erythematosus Following COVID-19 Infection
- Frontal fibrosing alopecia: a review of eleven patients
- Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
- The potential of Clausena anisata (Willd.) Hook.f. ex Benth against Propionibacterium acnes
- Safety of Common Medications for Treating Dermatology Disorders in Pregnant Women
- Baricitinib for the Treatment of Alopecia Areata
- Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
- Eyebrow and Eyelash Alopecia: A Clinical Review
- Comparing the frequency of isotretinoin-induced hair loss at <0.5-mg/kg/d versus ≥0.5-mg/kg/d dosing in acne patients: A systematic review
- Immune therapies for alopecia areata: evidence and new perspectives
- Refractory alopecia in lupus treated with tofacitinib — a case-based review
- Underactive bladder - an underestimated entity